Creative Medical Technology Holdings (NASDAQ:CELZ) Full Year 2023 Results
Main financial results
- Net loss: 5.29 million USD (48% loss reduction compared to FY2022).
- Loss of US$3.76 per share (improved from loss of US$9.28 in 2022).
All numbers shown in the chart above are for the trailing 12 month (TTM) period.
Creative Medical Technology Holdings' sales exceeded expectations, but EPS fell short
Sales exceeded analysts' expectations by 50%. Earnings per share (EPS) was 2.2% lower than analysts expected.
Looking ahead, revenues are expected to increase by an average of 61% per year over the next three years, compared to a growth forecast of 17% for the U.S. biotech industry.
performance of American biotechnology industry.
The company's stock price has fallen 3.2% from a week ago.
risk analysis
need to learn about. 3 warning signs We found Creative Medical Technology Holdings (two of which are a bit concerning).
Valuation is complex, but we help make it simple.
Please check it out Creative Medical Technology Holdings Could be overvalued or undervalued, check out our comprehensive analysis. Fair value estimates, risks and caveats, dividends, insider trading, and financial health.
See free analysis
Have feedback on this article? Curious about its content? contact Please contact us directly. Alternatively, email our editorial team at Simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts using only unbiased methodologies, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.
